share_log

ImmunoGen Announced Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO; Said Patient-Reported Outcomes With Mirvetuximab Versus Chemotherapy in FORWARD I Study Reinforces Differentiated Tolerability Profile

Benzinga Real-time News ·  Sep 11, 2022 07:58

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from an analysis of patient-reported outcomes (PROs) with mirvetuximab soravtansine (mirvetuximab) versus chemotherapy in the randomized Phase 3 FORWARD I study in platinum-resistant ovarian cancer. The Company also announced population pharmacokinetic (PK) and exposure response (ER) analyses across multiple clinical trials evaluating mirvetuximab monotherapy in folate receptor alpha (FRα)-positive ovarian cancer. These findings will be highlighted in three posters at the European Society for Medical Oncology (ESMO) Congress in Paris, France. "The data presented at...

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment